Immunome Inc reports results for the quarter ended September 30 - Earnings Summary

Immunome

14/11/2024 04:19

* Immunome Inc  IMNM.OQ  reported a quarterly adjusted loss
of 67
cents​​ per share for the quarter ended September 30.  The mean
expectation of six analysts for the quarter was for a loss of 56
cents per share. Wall Street expected results to range from -77
cents to -35 cents per share.
    * Revenue fell 18.4% to $2.91 million from a year ago;
analysts
expected $2.13 million. 
    * Immunome Inc's reported EPS for the quarter was a loss
of 78
cents​.
    * The company reported a quarterly loss of $47.1 million.
    * Immunome Inc shares had fallen by 14.6% this quarter and
gained 16.7% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 6 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is  "buy."

Wall Street's median 12-month price target for Immunome Inc is
$34.00 
This summary was machine generated from LSEG data November 14 at
04:19 a.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2024      -0.56          -0.67          Missed
 Jun. 30 2024      -0.39          -0.49          Missed
 Mar. 31 2024      -0.69          -2.51          Missed
 Dec. 31 2023      -0.28          -4.22          Missed